EHA: European Hematology Association
Conference Coverage
Novel anticoagulants linked to lower intracranial hemorrhages, higher GI bleeds
A real-life comparison of major bleeding risk with anticoagulants showed that in-hospital mortality was lower with novel oral agents than with...
Conference Coverage
Inherited thrombocytopenia type is a risk factor for hematologic cancers
ETV6-related thrombocytopenia (EV6-RT) appears to predispose carriers to acute lymphoblastic leukemia and other hematologic cancers.
Conference Coverage
Persistent post-therapy mutations may spark AML relapse
The higher risk of acute myeloid leukemia relapse among older patients may be due to persistent pre-leukemic mutations.
Conference Coverage
EHA: High-risk APL curable with chemo-free combo
Key clinical point: Arsenic trioxide plus all-trans retinoic acid is at least equivalent to all-trans retinoic acid and idarubicin in terms of...
Conference Coverage
CUDC-907 passes early hurdle in heavily pretreated lymphoma, myeloma
Key clinical point: The dual HDAC and Pi3K inhibitor CUDC-907 was reasonably tolerated and clinically active in a phase I study of heavily...
Conference Coverage
HSCT outcomes ‘encouraging’ in JAKi responders
Photo by Chad McNeeley VIENNA—Outcomes of hematopoietic stem cell transplant (HSCT) are encouraging in myelofibrosis (MF) patients who respond...
Conference Coverage
PI3Kδ/γ inhibitor generates rapid responses in CLL
VIENNA—New research indicates that duvelisib, a dual inhibitor of PI3Kδ and PI3Kγ, can generate rapid partial responses in treatment-naïve...
News
P13K inhibitors TGR-1202, duvelisib found clinically active in CLL
Key clinical point: The investigational P13K inhibitors TGR-1202 and duvelisib were clinically active in phase I trials. Major finding: TGR-1202...
Conference Coverage
Surgical bleeding risk ‘remarkable’ with platelet disorders
Key clinical point: Inherited platelet function disorders are associated with a significant surgical bleeding risk. Major finding: The frequency...
Conference Coverage
Advanced age no barrier to continuous myeloma regimen
Key clinical point: Patients over age 75 draw the same survival benefit with continuous lenalidomide plus low-dose dexamethasone over MPT as their...
Conference Coverage
Agent reduces fibrosis, improves platelet counts in MF
VIENNA—The immunotherapeutic agent PRM-151, when given alone or in combination with ruxolitinib, can reduce bone marrow fibrosis and improve...
Conference Coverage
Combo shows promise for heavily pretreated MM
Image by Louis Heiser and Robert Ackland VIENNA—Combining a novel agent with dexamethasone can produce successful results where other treatments...
Conference Coverage
Activin receptors continue to show efficacy in ß-thalassemia
Congress of the European Hematology Association VIENNA—Two very similar activin receptors, luspatercept and sotatercept, continue to show...
Conference Coverage
Drug won’t advance to phase 3 in ß-thalassemia
thalassemia VIENNA—Data from a phase 2a trial suggest the activin receptor sotatercept can effectively treat patients with ß-thalassemia....
Conference Coverage
Jury still out on combo for elderly AML
Photo courtesy of NIH VIENNA—A 2-drug combination can produce complete responses (CRs) in elderly patients with newly diagnosed acute myeloid...